Table 1.

Comparison Between Treatment Pattern Groups with Respect To Baseline and Post-baseline Variables of Interest

	Treated Continuously N= 86	Discontinued Treatment Early N=23	Treated Intermittently N=41	P-Value - Difference among 3 groups*	P-Value — Treated Continuously vs Discontinued treatment early*
Baseline Characteristics
Age, Years - Mean (SD)	70.5 (10.0)	60.9 (13.3)	66.7 (12.1)	0.001	<0.001
Female, N (%)	39 (45.3%)	8 (34.8%)	19 (46.3%)	0.62	0.36
Race				0.006	0.004
Black	4 (4.7%)	4 (17.4%)	8 (19.5%)
White	77 (89.5%)	14 (60.9%)	29 (70.7%)
Other	5 (5.8%)	5 (21.7%)	4 (9.8%)
Hispanic ethnicity	5 (5.8%)	3 (13.0%)	7 (17.1%)	0.12	0.24
CRVO disease type	76 (88.4%)	19 (82.6%)	32 (78.0%)	0.31	0.46
Mean disease duration (months), Mean (SD)	9.1 (17.7)	1.1 (2.2)	6.4 (11.9)	0.07	<0.001
w/ Diabetes	21 (24.4%)	11 (47.8%)	13 (31.7%)	0.09	0.03
w/ Hypertensive	62 (72.1%)	17 (73.9%)	31 (75.6%)	0.91	0.86
Aflibercept assignment	40 (46.5%)	11 (47.8%)	22 (53.7%)	0.75	0.91
Prior anti-VEGF treatment	32 (37.2%)	4 (17.4%)	13 (31.7%)	0.20	0.073
Visual Acuity Letter Score, Mean (SD)	52.6 (14.7)	51.0 (15.4)	48.2 (14.7)	0.31	0.66
Central Subfield thickness, μm – Mean (SD)	658 (232)	705 (268)	682 (214)	0.67	0.42
Month 01 Values
Change in VALS from baseline to M01
< 5	18 (20.9%)	3 (13.0%)	9 (22.5%)	0.29	0.39
5–9	18 (20.9%)	3 (13.0%)	3 (7.5%)
10 or more	50 (58.1%)	17 (73.9%)	28 (70.0%)
CST < 300 μm at M01	62 (73.8%)**	17 (73.9%)	24 (61.5%)***	0.35	0.99
Complete macular resolution at M01	24 (27.9%)	7 (30.4%)	7 (17.9%)***	0.42	0.81
Month 60 Values
Visual Acuity Letter Score, Mean (SD)	65.7 (21.3)	73.1 (24.4)	57.4 (26.7)	0.03	0.16
Central Subfield thickness, μm – Mean (SD)	275 (141)	209 (39)	262 (101)	0.07	<0.001
Complete macular resolution at M60	13(15.7%)!	16(69.6%)	6(15.0%)!!	<0.001	<.0001

^*P-values derived from ANOVA/t-test for continuous measures and Chi-Square tests for categorical.

^**Denominator is 84.

^***Denominator is 39.

^!denominator is 83.

^!!denominator is 40.